System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Francesco Patti is an expert in Neurology at University of Catania (Italy). As of October 2026, ScienceLeadR ranks Francesco Patti in the top 1% of experts worldwide for Multiple Sclerosis, Autoimmune Diseases and Epidemiologic Studies. Francesco Patti has authored 729 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 6 of them ongoing. SLR score: 2,204 (community average: 125). How the SLR is computed.

LeadR Profile

Francesco Patti University of Catania Italy
2 204 ScienceLeadR Reputation 2204

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Public Health - Neurosurgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1990 - 2026
Source: PubMed

University of Catania

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 729

Citations

Citations: 18 590 1st author: 78 Last author: 98 Unique author: 7

Main journals

Mult Scler 79
Neurology 78
J Neurol 54
Neurol Sci 50
J Neurol Sci 32

Best Journals

Lancet Neurol 3
N Engl J Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry.
PMID 42881253 — registries, antibodies, myelitis, phenotype, neurosurgery, neuromyelitis optica, rituximab, antibodies, monoclonal, sex, therapeutics, neurology		J Neurol20260
Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry.
PMID 42873203 — registries, sclerosis, multiple sclerosis, intelligence, research, therapeutics, artificial intelligence, generative artificial intelligence		Mult Scler20260
How patients with neuromyelitis optica spectrum disease accumulate disability.
PMID 42847346 — multiple sclerosis, absenteeism, central nervous system diseases, cohort studies, neuromyelitis optica, demyelinating diseases		Mult Scler20260
Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model.
PMID 42828703 — sclerosis, multiple sclerosis, therapeutics		Neurol Ther20260
Incidence of Multiple Sclerosis in the City of Catania: A 50-Year Observational Population-Based Study.
PMID 42664189 — sclerosis, multiple sclerosis, incidence, age of onset		Neuroepidemiology20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 12
N/A 4
Phase 2 4
Phase 4 1

By status:

Completed 9
Active not recruiting 6
Recruiting 4
Terminated 2

By type:

Interventional 18
Observational 3

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 2
multicentricup10 18

Main Topics

Cohort/Consortium Investigators 19

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis
2023-506516-40-00 — sclerosis, multiple sclerosis, safety, adolescent, multiple sclerosis, relapsing-remitting, child		Phase 3Active not recruiting2022
A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis
2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis		Phase 3Active not recruiting2024
A Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Satralizumab in Patients with Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease
2023-507196-22-00 — oligodendroglia, safety, myelin-oligodendrocyte glycoprotein, glycoproteins, therapeutics, pharmacokinetics		Phase 3Active not recruiting2022
Efficacy and Safety Study of Nipocalimab for Adults with CIDP
2023-508425-28-00 — safety, polyneuropathies, polyradiculoneuropathy, chronic inflammatory demyelinating		Phase 2Recruiting2022
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
2024-517529-26-00 — safety, polyneuropathies		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS